newsfilter
← Latest News
GlobeNewswire·

Invivyd Reports Second Quarter 2026 Financial Results and Recent Business Highlights

Achieved Q2 2026 PEMGARDA® (pemivibart) net product revenue of $14.3 million, representing 21% growth versus Q2 2025 net product revenue of $11.8 millionCompleted rapid enrollment in VYD2311 DECLARATION clinical trial